These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 34843388)

  • 1. Population Pharmacokinetic and Concentration-QTc Analysis of Delamanid in Pediatric Participants with Multidrug-Resistant Tuberculosis.
    Sasaki T; Svensson EM; Wang X; Wang Y; Hafkin J; Karlsson MO; Mallikaarjun S
    Antimicrob Agents Chemother; 2022 Feb; 66(2):e0160821. PubMed ID: 34843388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population Pharmacokinetics of Delamanid and its Main Metabolite DM-6705 in Drug-Resistant Tuberculosis Patients Receiving Delamanid Alone or Coadministered with Bedaquiline.
    Tanneau L; Karlsson MO; Diacon AH; Shenje J; De Los Rios J; Wiesner L; Upton CM; Dooley KE; Maartens G; Svensson EM
    Clin Pharmacokinet; 2022 Aug; 61(8):1177-1185. PubMed ID: 35668346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial.
    Dooley KE; Rosenkranz SL; Conradie F; Moran L; Hafner R; von Groote-Bidlingmaier F; Lama JR; Shenje J; De Los Rios J; Comins K; Morganroth J; Diacon AH; Cramer YS; Donahue K; Maartens G;
    Lancet Infect Dis; 2021 Jul; 21(7):975-983. PubMed ID: 33587897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population Pharmacokinetic Analysis of Delamanid in Patients with Pulmonary Multidrug-Resistant Tuberculosis.
    Wang X; Mallikaarjun S; Gibiansky E
    Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33106258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cumulative Fraction of Response for Once- and Twice-Daily Delamanid in Patients with Pulmonary Multidrug-Resistant Tuberculosis.
    Mallikaarjun S; Chapagain ML; Sasaki T; Hariguchi N; Deshpande D; Srivastava S; Berg A; Hirota K; Inoue Y; Matsumoto M; Hafkin J; Geiter L; Wang X; Gumbo T; Liu Y
    Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33106263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delamanid Added to an Optimized Background Regimen in Children with Multidrug-Resistant Tuberculosis: Results of a Phase I/II Clinical Trial.
    Garcia-Prats AJ; Frias M; van der Laan L; De Leon A; Gler MT; Schaaf HS; Hesseling AC; Malikaarjun S; Hafkin J
    Antimicrob Agents Chemother; 2022 May; 66(5):e0214421. PubMed ID: 35404075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).
    Liu Y; Matsumoto M; Ishida H; Ohguro K; Yoshitake M; Gupta R; Geiter L; Hafkin J
    Tuberculosis (Edinb); 2018 Jul; 111():20-30. PubMed ID: 30029909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delamanid: a review of its use in patients with multidrug-resistant tuberculosis.
    Blair HA; Scott LJ
    Drugs; 2015 Jan; 75(1):91-100. PubMed ID: 25404020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delamanid when other anti-tuberculosis-treatment regimens failed due to resistance or tolerability.
    Kwon YS; Jeong BH; Koh WJ
    Expert Opin Pharmacother; 2015 Feb; 16(2):253-61. PubMed ID: 25327169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delamanid for multidrug-resistant pulmonary tuberculosis.
    Gler MT; Skripconoka V; Sanchez-Garavito E; Xiao H; Cabrera-Rivero JL; Vargas-Vasquez DE; Gao M; Awad M; Park SK; Shim TS; Suh GY; Danilovits M; Ogata H; Kurve A; Chang J; Suzuki K; Tupasi T; Koh WJ; Seaworth B; Geiter LJ; Wells CD
    N Engl J Med; 2012 Jun; 366(23):2151-60. PubMed ID: 22670901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study.
    Ferlazzo G; Mohr E; Laxmeshwar C; Hewison C; Hughes J; Jonckheere S; Khachatryan N; De Avezedo V; Egazaryan L; Shroufi A; Kalon S; Cox H; Furin J; Isaakidis P
    Lancet Infect Dis; 2018 May; 18(5):536-544. PubMed ID: 29452942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delamanid for the treatment of pulmonary multidrug-resistant tuberculosis.
    Thakare R; Soni I; Dasgupta A; Chopra S
    Drugs Today (Barc); 2015 Feb; 51(2):117-23. PubMed ID: 25756067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delamanid: first global approval.
    Ryan NJ; Lo JH
    Drugs; 2014 Jun; 74(9):1041-5. PubMed ID: 24923253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis.
    Skripconoka V; Danilovits M; Pehme L; Tomson T; Skenders G; Kummik T; Cirule A; Leimane V; Kurve A; Levina K; Geiter LJ; Manissero D; Wells CD
    Eur Respir J; 2013 Jun; 41(6):1393-400. PubMed ID: 23018916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Six-Month Response to Delamanid Treatment in MDR TB Patients.
    Hewison C; Ferlazzo G; Avaliani Z; Hayrapetyan A; Jonckheere S; Khaidarkhanova Z; Mohr E; Sinha A; Skrahina A; Vambe D; Vasilyeva I; Lachenal N; Varaine F
    Emerg Infect Dis; 2017 Oct; 23(10):1746-8. PubMed ID: 28767036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and preclinical evaluations of JBD0131, a novel nitrodihydro-imidazooxazole anti-tuberculosis agent.
    Luo W; Huang Z; Xu D; Yang M; Zhu Y; Shen L; Chen S; Tao X; Bin W; Hu Y; Franzblau SG; Jiang N; Wei Y; Wei X; Ding CZ
    Bioorg Med Chem Lett; 2022 Sep; 72():128871. PubMed ID: 35777718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
    Wirth D; Dass R; Hettle R
    BMC Health Serv Res; 2017 Mar; 17(1):182. PubMed ID: 28270207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of bedaquiline and delamanid in diabetes patients: clinical and pharmacological considerations.
    Hu M; Zheng C; Gao F
    Drug Des Devel Ther; 2016; 10():3983-3994. PubMed ID: 27994440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current Status of Delamanid in the Management of MDR Tuberculosis.
    Karekar SR; Marathe PA
    J Assoc Physicians India; 2018 Jul; 66(7):72-75. PubMed ID: 31325268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bedaquiline and delamanid in tuberculosis.
    Esposito S; Bianchini S; Blasi F
    Expert Opin Pharmacother; 2015; 16(15):2319-30. PubMed ID: 26293803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.